title: [Streptozotocin and malignant insulinomas. Apropos of the case. Review of the literature].
abstract: In spite of possible toxicity streptozotocin now appears to be the best treatment for malignant islet cell tumour with liver metastases, i.e. inoperable tumours with a poor prognosis either due to extension of the tumour itself or due to hypoglycemic attacks. Out of about 60 patients thus treated, 1 to 2 years survival were obtained. 22 out of 52 patients reported by Broder and Carter are still alive and one may estimate the overall percentage of favourable results at 65%. On the other hand out of another 100 patients treated elsewhere with this antineoplastic agent, only a few cases of carcinoid tumour gave encouraging results. The course of the others was not modified significantly.
mesh_terms: D007516:Adenoma, Islet Cell / Q000150:complications / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D056486:Chemical and Drug Induced Liver Injury; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010190:Pancreatic Neoplasms / Q000150:complications / Q000188:drug therapy*; D013311:Streptozocin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D013311:Streptozocin
vernacular_title: Streptozotocine et insulinomes malins. A propos d'un cas. Revue de la littérature